Mota Ali, Hemati-Dinarvand Mohsen, Akbar Taheraghdam Ali, Reza Nejabati Hamid, Ahmadi Ravan, Ghasemnejad Tohid, Hasanpour Milad, Valilo Mohammad
Department of Biochemistry and Clinical Laboratories, Faculty of Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Department of Biochemistry and Clinical Laboratories, Faculty of Medical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
Acta Neurol Taiwan. 2019 Sep 15;28(3):66-74.
Various numbers of factors such as oxidative stress, neurotoxins, and pesticides have been implicated in its pathophysiology of Parkinson's disease (PD). Paraoxonas1 (PON1) metabolizes xenobiotics, including pesticides. Therefore, we surveyed the relationship between PON1 polymorphisms with its activities in the pathogenesis of Parkinson's disease..
We investigated polymorphisms of the PON1 (L55M and Q192R) by PCR-RFLP assays; we also measure the levels of PON1, TAC (total antioxidant capacity) and TOS (total oxidant status) with ELISA (Enzyme-linked immunosorbent assay) and spectrophotometric method for their activities.
Paraoxonase and arylesterase activity of PON1 as well as their concentrations were lower in patients with PD compared with control group, but from the view of the specific activity, it was not significant between two groups. In the compare of TAC, TOS, and OSI, the TOS and OSI were higher in the patients than controls, while patients had lower levels of TAC compared with controls. Serum PON1 concentrations and activities were higher in LL (comparison with LM and MM) and RR (comparison with QR and QQ) genotypes while we did not observe any significant differences in arylesterase levels among mentioned polymorphisms.
In the current study, we reported associations between PON1 polymorphisms (55, 192) and enzyme activities in Parkinson's disease as there was a significant reduction in PON1 levels in patients with Parkinson compared with healthy. Taken together, paraoxonase enzyme in subjects with different genotypes could be a potential biomarker for determining the severity and prognosis of Parkinson. However, more studies are needed to clarify its clinical values. Key words: Parkinson's disease; paraoxonase1; Polymorphism.
氧化应激、神经毒素和农药等多种因素与帕金森病(PD)的病理生理学有关。对氧磷酶1(PON1)可代谢包括农药在内的外源性物质。因此,我们调查了PON1基因多态性与其活性在帕金森病发病机制中的关系。
我们通过聚合酶链反应-限制性片段长度多态性分析(PCR-RFLP)检测PON1(L55M和Q192R)的多态性;我们还采用酶联免疫吸附测定(ELISA)和分光光度法测量PON1、总抗氧化能力(TAC)和总氧化状态(TOS)的水平以评估其活性。
与对照组相比,帕金森病患者的PON1对氧磷酶和芳基酯酶活性及其浓度较低,但从比活性来看,两组之间无显著差异。在比较TAC、TOS和氧化应激指数(OSI)时,患者的TOS和OSI高于对照组,而患者的TAC水平低于对照组。LL基因型(与LM和MM比较)和RR基因型(与QR和QQ比较)的血清PON1浓度和活性较高,而我们未观察到上述多态性之间的芳基酯酶水平有任何显著差异。
在本研究中,我们报告了帕金森病中PON1基因多态性(55、192)与酶活性之间的关联,因为与健康人相比,帕金森病患者的PON1水平显著降低。综上所述,不同基因型受试者的对氧磷酶可能是确定帕金森病严重程度和预后的潜在生物标志物。然而,需要更多研究来阐明其临床价值。关键词:帕金森病;对氧磷酶1;多态性